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Estrogen receptors (ERs) mediate most of the biolog-
ical effects of estrogen in mammary and uterine epithe-
lial cells by binding to estrogen response elements in the
promoter region of target genes or through protein-pro-
tein interactions. Anti-estrogens such as tamoxifen in-
hibit the growth of ER-positive breast cancers by reduc-
ing the expression of estrogen-regulated genes.
However, anti-estrogen-resistant growth of ER-positive
tumors remains a significant clinical problem. Here we
show that phosphatidylinositol (PI) 3-kinase and AKT
activate ERa in the absence of estrogen. Although PI
3-kinase increased the activity of both estrogen-inde-
pendent activation function 1 (AF-1) and estrogen-
dependent activation function 2 (AF-2) of ERa, AKT
increased the activity of only AF-1. PTEN and a catalyt-
ically inactive AKT decreased PI 3-kinase-induced AF-1
activity, suggesting that PI 3-kinase utilizes AKT-
dependent and AKT-independent pathways in activat-
ing ERa. The consensus AKT phosphorylation site Ser-
167 of ERa is required for phosphorylation and
activation by AKT. In addition, LY294002, a specific in-
hibitor of the PI 3-kinase/AKT pathway, reduced phos-
phorylation of ERa in vivo. Moreover, AKT overexpres-
sion led to up-regulation of estrogen-regulated pS2 gene,
Bcl-2, and macrophage inhibitory cytokine 1. We dem-
onstrate that AKT protects breast cancer cells from ta-
moxifen-induced apoptosis. Taken together, these re-
sults define a molecular link between activation of the
PI 3-kinase/AKT survival pathways, hormone-indepen-
dent activation of ERa, and inhibition of tamoxifen-in-
duced apoptotic regression.
Estrogen-induced proliferation of mammary and uterine ep-
ithelial cells is primarily mediated by estrogen receptors
(ERs),1 which belong to steroid/thyroid hormone superfamily of
transcription factors (1). ERs, through their estrogen-indepen-
dent and estrogen-dependent activation domains (AF-1 and
AF-2, respectively), regulate transcription by recruiting coacti-
vator proteins and interacting with the general transcriptional
machinery (2). Tamoxifen, which functions as a cell type-spe-
cific anti-estrogen, competitively binds to ERa and inhibits
estrogen-stimulated growth of mammary epithelial cells. De-
pending on the concentration of tamoxifen, growth-arrested
cells undergo apoptosis within 24 h or after 72 h of tamoxifen
treatment (3). Although most ERa-positive breast cancers ini-
tially respond to tamoxifen therapy, tamoxifen-resistant tu-
mors eventually develop (4). It has been shown previously that
growth factors such as epidermal growth factor (EGF), insulin-
like growth factor (IGF-1), and heregulin confer estrogen-inde-
pendent growth properties to ERa-positive breast cancer cells
(5–7). It is suggested that EGF- and IGF-1-induced mitogen-
activated protein kinase (MAPK) phosphorylates Ser-118 of
ERa, increases the activity of AF-1, and confers hormone-
independent growth (6). However, a recent study indicates
that, although prolonged activation of MAPK is growth inhib-
itory in breast cancer cells, parallel activation of the PI 3-ki-
nase/AKT pathway by EGF and IGF-1 is sufficient to overcome
such inhibition (8). Therefore, these growth factors may utilize
the PI 3-kinase/AKT pathway to activate ERa and confer hor-
mone-independent growth.
Growth factor-dependent survival of a wide variety of cul-
tured cells types ranging from fibroblasts to neurons is depend-
ent on PI 3-kinase pathway (9). Growth factor-induced activa-
tion of transmembrane receptors (IGF-1, EGF, platelet-derived
growth factor, basic fibroblast growth factor, and heregulin)
results in recruitment of PI 3-kinase to the plasma membrane
(9). In the plasma membrane, PI 3-kinase promotes generation
of 39-phosphorylated phosphoinositides, which in turn bind to
AKT. AKT bound to phosphoinositides is translocated from
cytoplasm to the plasma membrane, where it is activated
through phosphorylation. Apart from growth factors, estrogen
also activates AKT by triggering the binding of ERa to the p85
regulatory subunit of PI 3-kinase (10). However, induction of
AKT by estrogen is cell type-specific, as it is not observed in
MCF-7 breast cancer cells (11). Activated AKT promotes cell
survival by phosphorylating and modulating the activity of
various transcription factors in the nucleus. The tumor sup-
pressor PTEN gene, which dephosphorylates 39-phosphoryl-
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ated phosphoinositides in vivo, inhibits AKT activation (12).
Several clinical and laboratory observations prompted us to
study whether ERa is the target of AKT and whether AKT
protects breast cancer cells against tamoxifen-induced apopto-
sis. For example, PI 3-kinase and AKT amplification is ob-
served in breast and ovarian cancer (13–15). Cowden disease
patients, who have a germ line-inactivating PTEN mutation,
display increased breast cancer risks (16). Similarly, PTEN
mutation is observed in endometrial cancer (17). Moreover,
IGF-1 and heregulin, whose overexpression correlates with
tamoxifen resistance, activate AKT (5, 7). Finally, serine at
amino acid position 167 of ERa is a consensus AKT phospho-
rylation site (RXRXX(S/T)) (9). In this report, we show that
AKT phosphorylates Ser-167 of ERa and confers tamoxifen
resistance.
EXPERIMENTAL PROCEDURES
Cell Culture—MCF-7 cells were grown in minimal essential medium
(MEM) containing phenol red (PR), 10% fetal calf serum (FCS), strep-
tomycin, and penicillin. COS-1 cells were maintained in Dulbecco’s
modified MEM (DMEM) including PR, 10% FCS, streptomycin, and
penicillin.
Recombinant Plasmids, DNA Transfections, and CAT Assays—
MCF-7 and COS-1 cells were passed 24 h prior to transfection in
PR-free DMEM 1 5% charcoal/dextran-treated serum (CCS) and trans-
fected via the calcium phosphate method. The b-galactosidase expres-
sion vector RSV/b-galactosidase (2 mg) was cotransfected as an internal
control. In all transfections, the total amount of expression vector was
kept constant by substituting with appropriate empty expression vec-
tor. Fresh media (PR-free MEM 1 5% CCS for MCF-7, PR-free DMEM
1 5% CCS for COS-1 cells) along with appropriate drugs were added
24 h after transfection. Cells were harvested 36 h after transfection and
CAT activity in equal numbers of b-galactosidase units was determined
as described previously (18). ERE3-TK-CAT, GAL-AB and GAL-EF
were gifts from P. Chambon and described previously (19). The CA-AKT
expression vector that lacks pleckstrin homology domain (amino acids
4–129) of AKT and KD-AKT expression vector that contains S179M
FIG. 1. AKT specifically increases estrogen-independent activ-
ity of ERa. A, MCF-7 cells were transfected with 5 mg of ERE3-TK-
CAT and 1 mg of pcDNA3, CA-AKT, or KD-AKT. Cotransfection of AKT
led to increases in estrogen-independent activity and further increases
in estrogen-stimulated (E2, 1028 M) activity of ERa. *, p 5 0.0019; **,
p 5 ,0.0001; and ***, p 5 0.07 for CA-AKT versus pcDNA3 in the
absence and presence of estrogen and 4-HT, respectively. Western blot
analysis of extracts used in a representative CAT assay for CA-AKT
expression is shown. B, PI 3-kinase-dependent increases in ERE3-TK-
CAT activity. Western blot of p85 subunit of PI 3-kinase that coprecipi-
tates with p110 subunit is also shown. *, p 5 0.0019 for untreated PI
3-kinase versus untreated pcDNA3 cells. **, p 5 0.0008 for estrogen-
treated PI 3-kinase versus estrogen-treated pcDNA3 cells. ***, p 5
0.0238 for 4-HT-treated PI 3-kinase cells versus 4-HT-treated pcDNA3
cells. C, AKT had no effect on retinoic acid (1026 M) inducible-expression
of b-RARE-TK-CAT. In contrast, PI 3-kinase increased b-RARE-TK-
CAT activity in the absence of retinoic acid.
FIG. 2. AF-1 is target for AKT. COS-1 cells were transfected with
GAL-DBD (pM), GAL-AB, or GAL-EF along with pG5/CAT and RSV/b-
galactosidase. GAL-AB activity in the absence of CA-AKT is set arbi-
trarily as 10 units. GAL-AB activity increased by 3.5-fold in the pres-
ence of CA-AKT. GAL-EF activity was not affected by AKT and was
appreciated only in estrogen-treated (1028 M) cells. CA-AKT expression
level in transfected cells is shown.
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substitution have been described previously (20) and were gifts from R.
Roth. COS-1 cell transfections were performed with the original SV40
enhancer-promoter-driven CA-AKT and KD-AKT expression vectors.
pcDNA3 derivatives of CA-AKT and KD-AKT were generated and used
in MCF-7 cell transfections. Constitutively active PI 3-kinase vector,
which contains murine p110a cDNA with avian Src myristoylation
signal at the N terminus (21), was a gift from S. Boswell. PTEN
expression vector was a gift from J. Dixon.
Phosphorylation of GST-AB by AKT in Vitro—Amino acids 1–184 of
ERa were cloned in frame to pGEX-2T vector to obtain recombinant
GST-AB. AKT-kinase assay with recombinant GST, GST-AB, or AB
obtained after cleaving GST-AB with thrombin in the presence of
[g-32P]ATP was performed as per AKT manufacturer’s recommenda-
tions (Upstate Biotechnology, Inc.).
AKT-overexpressing Clones and Growth Analysis—MCF-7 cells were
transfected with either empty pcDNA3 or pcDNA3 vector encoding
CA-AKT. Transfected cell populations were selected using G418 (0.6
mg/ml) and CA-AKT expression in individual G418-resistant colonies
was verified by Western analysis. MCF-7 control (pcDNA-1) and CA-
AKT (CA-AKT-4) cells were plated in MEM with PR and 10% FCS at a
density of 2 3 105 cells/60-mm plate. After 24 h, fresh medium contain-
ing either 1028 M estradiol or 1026 M 4-HT or 1027 M ICI-182,780 was
added and replaced every 48 h with appropriate drugs. At 72, 96, and
120 h, cells were collected by trypsinization, stained with trypan blue,
and counted twice using a hemocytometer. All experiments were per-
formed in triplicate.
Cell Cycle Analysis and Quantitation of Apoptosis—MCF-7 control
and CA-AKT cells were plated at a density of 1 3 105 cells/60-mm dish
in MEM with PR 1 10% FCS. After 24 h, fresh medium was added,
along with 1026 M 4-HT. Cell cycle analysis utilizing propidium iodide
staining was performed at specific intervals. Apoptosis of untreated and
4-HT-treated (1026 M for 72 h) control and CA-AKT cells was measured
by annexin V labeling and fluorescence microscopy, as per manufactur-
er’s recommendations (annexin V-EGFP, BioVision).
Western Blot Analysis and Immunoprecipitation—Western blotting/
immunoprecipitation of cell lysates with antibodies against cyclin D1,
PTEN (Santa Cruz), Bcl-XL, BAX, BAK (Trevigen), Bcl-2 (PharMingen),
PI3K-p110, p85 (Upstate Biotechnology, Inc.), AKT (New England Bio-
labs), and a-tubulin (Sigma) was performed as per manufacturer’s
recommendations. ERa antibodies were from either P. Chambon’s lab-
oratory or from Chemicon.
Orthophosphate Labeling and Immunoprecipitation of ERa—ERa
cDNA was first cloned into pCMV4 expression vector, which is similar
to pcDNA3, except that it contains a translational enhancer from alfalfa
mosaic virus 4. 293 cells were transfected with either empty expression
vector or pCMV4-ERa. After maintaining cells for 48 h in PR-free
DMEM with 5% CCS, cells were serum-starved in PR-free, phosphate-
free DMEM for 24 h. Cells were incubated with orthophosphate and
either Me2SO or 20 mM LY294002. IGF-1 (100 ng/ml, R&D Systems) was
added after 1 h, and cells were harvested after an additional 1 h. ERa
was immunoprecipitated and subjected to autoradiography, followed by
Western blotting with ERa antibody.
Statistical Analysis—Data were analyzed with StatView (version
4.1). Analysis of variance was employed to determine p values between
mean measurements. A p value , 0.05 was deemed significant. Error
bars on all histograms in this text represent standard deviations be-
tween measurements from duplicate experiments.
RESULTS
AKT Confers Ligand-independent Activity to ERa—To inves-
tigate the ability of AKT to directly regulate ERa activity,
ERa-positive MCF-7 breast cancer cells were transiently trans-
fected with a CAT reporter gene under the control of a thymi-
dine kinase promoter and three ERE elements (ERE3-TK-
CAT). Estrogen increased ERE3-TK-CAT activity 6-fold,
whereas 4-hydroxytamoxifen (4-HT) had no effect (Fig. 1A).
Cotransfection of a constitutively active AKT expression vector
(CA-AKT) resulted in 4.5- and 15-fold increases in ERE3-TK-
CAT activity in the absence and presence of estrogen, respec-
tively (Fig. 1A). Cotransfection of a catalytically inactive AKT
vector (KD-AKT) affected neither estrogen-dependent nor es-
trogen-independent ERE3-TK-CAT activity. These results sug-
gest that AKT confers estrogen-independent activity and fur-
ther increases estrogen-stimulated activity of ERa. Note that
AKT-mediated estrogen-independent ERE3-TK-CAT activity
was reduced to 2.5-fold by 4-HT.
A substantial (4-fold) increase in estrogen-independent ac-
tivity was observed when ERE3-TK-CAT was transfected along
with PI 3-kinase, the upstream activator of AKT (Fig. 1B). PI
3-kinase-induced ERE3-TK-CAT activity was reduced to 2.5-
fold by 4-HT. CA-AKT had no effect on basal and retinoic
acid-inducible expression of b-RARE-TK-CAT (a TK promoter
with a retinoic acid response element from the b-retinoic acid
receptor) (18). In contrast, PI 3-kinase increased b-RARE-TK-
CAT activity in the absence of retinoic acid (Fig. 1C). These
results suggest that, although AKT overexpression leads to a
FIG. 3. PI 3-kinase activates AF-1 and AF-2 via AKT-dependent
and AKT-independent mechanisms, respectively. COS-1 cells
were transfected with the indicated plasmids and pG5/CAT reporter. A,
note that PI 3-kinase increased both GAL-AB and GAL-EF activity. In
addition, KD-AKT reduced PI 3-kinase-induced GAL-AB activity, indi-
cating that PI 3-kinase utilizes AKT to activate AF-1. B, PTEN reduced
PI 3-kinase-induced GAL-AB activity, suggesting that activation of
AF-1 by PI 3-kinase requires the presence of AKT. Expression levels of
endogenous and transfected genes are shown.
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specific increase in ERa activity, PI 3-kinase overexpression
may lead to a global change in nuclear receptor activity, pos-
sibly through activation of coactivators (2, 22).
AKT Increases AF-1 Activity—To determine the activation
domains of ERa required for estrogen-independent activation
by AKT, we utilized expression vectors that code for a fusion
protein containing the DNA binding domain (DBD) of yeast
transcription factor GAL-4 and either the AF-1 domain (GAL-
AB) or AF-2 domain of ERa (GAL-EF) (19). A CAT reporter
gene under the control of a TATA box and five binding sites for
GAL-4 DBD (pG5/CAT) was cotransfected with either
GAL(DBD) alone (pM), GAL-AB, or GAL-EF with or without
CA-AKT. COS-1 cells were used because they provide an ERa-
free background. CA-AKT increased GAL-AB activity by ;3.5-
fold, which was not influenced by estrogen (Fig. 2). GAL-EF
activity was observed only in estrogen-treated cells and was not
affected by AKT. These results demonstrate that AKT specifi-
cally increases AF-1 activity and are consistent with previously
described EGF- and IGF-1-regulated enhancement of AF-1 ac-
tivity (6).
PI 3-Kinase Increases Both AF-1 and AF-2 Activity—PI 3-ki-
nase, apart from AKT, activates other signaling pathways in-
cluding Jun N-terminal kinase, protein kinase Cl and protein
kinase Cz, which may contribute to a PI 3-kinase-mediated
increase in ERa activity (23–25). To test this hypothesis, we
transfected COS-1 cells with pG5/CAT, GAL-AB, or GAL-EF
and a constitutively active PI 3-kinase (Fig. 3A). PI 3-kinase
increased GAL-AB activity by ;8-fold. Cotransfection with KD-
AKT resulted in reduction of PI 3-kinase-induced GAL-AB
activity. PTEN, a negative regulator of PI 3-kinase-mediated
activation of AKT (12), also showed a concentration-dependent
reduction of PI 3-kinase-induced GAL-AB activity (Fig. 3B).
For unknown reasons, we observed reduced levels of PI 3-ki-
nase p110zp85 complex in cells transfected with 5 mg of PTEN
(Fig. 3B, bottom panel). Therefore, it is not clear whether re-
duction in GAL-AB activity by PTEN involves only its lipid
FIG. 4. AKT directly phosphorylates
AF-1. A, phosphorylation of recombinant
AB by purified AKT in vitro. Recombinant
GST, AB, or AB mutants were incubated
with recombinant AKT and [g-32P]ATP.
Kinase reactions were run on an SDS-
PAGE, transferred to nitrocellulose, and
subjected to both autoradiography (top)
and staining with Coomassie Blue (bot-
tom). B, effect of LY294002 on ERa phos-
phorylation. Orthophosphate-labeled
ERa from 293 cells transfected with ei-
ther vector alone or pCMV4-ERa was
identified by immunoprecipitation and
autoradiography (lanes 1–4). Western
blot analysis of the same blot for ERa
protein is also shown. Relative phospho-
rylation in each reaction was calculated
by densitometric scanning and normaliz-
ing for ERa level. Orthophosphate-la-
beled proteins that coprecipitate with
ERa are also shown (lanes 5–8). NS, non-
specific. C, serine 167 in the AB domain is
essential for AKT-mediated activation.
COS-1 cells were transfected with either
GAL-AB or mutants as in Fig. 2. AB-
S167A mutant in which serine 167 is mu-
tated to alanine was not activated by CA-
AKT. Wild type and mutant GAL-AB
proteins are expressed at a similar level
in transfected cells (data not shown).
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phosphatase activity or other biological activity. Nonetheless,
PTEN overexpression resulted in reduction in AKT activity in
transfected cells (data not shown). Interestingly, GAL-EF,
which was not induced by AKT (Fig. 2), was activated by PI
3-kinase both in the absence and presence of estrogen (Fig. 3A).
Moreover, KD-AKT failed to reduce GAL-EF activation by PI
3-kinase, suggesting that activation of AF-1 (but not AF-2) by
PI 3-kinase is, at least in part, AKT-dependent (Fig. 3A).
Ser-167 of ERa Is Essential for Phosphorylation and Activa-
tion by AKT—Phosphorylation of the AF-1 domain of ERa by
AKT was investigated using purified AKT and a recombinant
protein containing the AF-1 domain fused to glutathione
S-transferase (GST-AB). GST and GST-AB proteins were incu-
bated with [g-32P]ATP and recombinant AKT. GST-AB but not
GST was phosphorylated by AKT, thereby confirming direct
phosphorylation of AF-1 by AKT (data not shown). Mass spec-
trometry followed by mutation analysis revealed that AKT
fortuitously phosphorylates Ser-173 or Ser-178 of AF-1 within
the context of GST-AB fusion protein (data not shown). There-
fore, purified wild type AB or mutants lacking GST were used
in in vitro kinase assays. Mutation of Ser-167 (AB-S167A) but
not Ser-118 (AB-S118A), Ser-173 (AB-S173A), Ser-178 (AB-
A178A), and Ser-173/Ser-178 (AB-S173A,S178A) to alanine
prevented phosphorylation by AKT (Fig. 4A). Ser-167 is a con-
sensus AKT phosphorylation site (RXRXX(S/T)), which is also
phosphorylated by p90RSK1 (26), and is the major phosphoryl-
ation site of ERa in MCF-7 cells (27).
We next determined whether basal or IGF-1-induced phos-
phorylation of ERa is dependent on PI 3-kinase/AKT pathway.
Human embryonic kidney cells 293 transfected with ERa ex-
pression vector were labeled with [32P]orthophosphate and
treated with Me2SO, IGF-1, or LY294002 1 IGF-1. LY294002
is a specific inhibitor of PI 3-kinase/AKT pathway. Although
IGF-1 treatment led to only marginal increase in overall ERa
phosphorylation, LY294002 inhibited ERa phosphorylation
(Fig. 4B). The effect of LY294002 is specific to ERa, as phos-
phorylation of an unknown protein that coprecipitates with
ERa was similar in both untreated and LY294002-treated cells
(Fig. 4B, lanes 5–8, indicated by **). These results further
suggest the involvement of PI 3-kinase/AKT pathway in phos-
phorylation of ERa.
We next compared AKT-mediated activation of wild type
GAL-AB and GAL-AB mutants lacking Ser-102, Ser-104, and
Ser-106 (AB-S102N,S104P,S106A), Ser-118 (AB-S118A), Ser-
167 (AB-S167A), or Ser-173 and Ser-178 (AB-S173A,S178A).
Only AB-S167A did not respond to AKT, suggesting that Ser-
167 is essential for activation of AF-1 by AKT (Fig. 4C). Muta-
tion of Ser-167 to alanine also reduced estrogen-independent
and/or estrogen-dependent activity of full-length ERa in
COS-1, MDA-MB-231, and HeLa cells (data not shown). AKT-
mediated activation of AB-S102N, S104P, S106A, and AB-
S118A was also lower than the wild type, which could be due to
reduced basal activity of these mutants. Alternatively, activa-
tion of AF-1 by AKT is partially dependent on phosphorylation
of AB by cdk2/cyclinA or MAPK (6, 28). In this regard, we have
observed that mutation of both cdk2/cyclin A and AKT phos-
phorylation sites severely compromised ligand-independent ac-
tivity of full-length ERa in MDA-MB-231 cells.2
Endogenous Estrogen-regulated pS2 Gene Expression Is Up-
regulated by AKT—To study whether CA-AKT induces the
expression of endogenous estrogen-regulated genes, we gener-
ated MCF-7 cells overexpressing CA-AKT (Fig. 5A). We meas-
ured the expression of pS2 and c-Myc in untreated, estrogen-,
4-HT-, and estrogen14-HT-treated cells. The basal level of pS2
was higher in CA-AKT-4 cells compared with pcDNA3–2 and
CA-AKT-2 cells (Fig. 5B). Estrogen-inducible expression of pS2
was higher in both CA-AKT-2 and CA-AKT-4 cells compared
with pcDNA3 cells. Note that CA-AKT-4 cells express higher
level of AKT than CA-AKT-2 cells (Fig. 5A). As with the results
of transient transfection assays, constitutive and estrogen-in-
ducible expression of pS2 was repressed by 4-HT. Interestingly,
AKT overexpression did not result in changes in c-Myc
expression.
Screening of Atlas Human Cancer cDNA expression array
using RNA from pcDNA3 and CA-AKT cells revealed up-regu-
lation of macrophage inhibitory cytokine (MIC-1) by AKT (29).
This was confirmed by Northern blotting (Fig. 5B). MIC-1
expression was observed only in CA-AKT-4 cells, which was
increased modestly by estrogen. Interestingly, 4-HT did not
suppress MIC-1 expression. Taken together, these results sug-
gest that AKT increases either constitutive or estrogen-induc-
ible expression of specific estrogen-responsive genes.
AKT Confers Tamoxifen Resistance to MCF-7 Cells—Because
AKT increases AF-1 activity and AF-1 is implicated in tamox-
ifen resistance, we studied the 4-HT sensitivity of pcDNA3–1
and CA-AKT-4 cells (Fig. 6A). Growth rates for untreated,
estrogen- (1028 M), 4-HT- (1026 M), and estrogen14-HT-treated
cells were determined at specific intervals. As expected, estro-
gen stimulated the growth of both pcDNA3 and CA-AKT cells.
2 H. Nakshatri, manuscript in preparation.
FIG. 5. AKT increases pS2 and MIC-1 expression. A, MCF-7 cells
stably overexpressing AKT (CA-AKT-2, CA-AKT-4) and empty vector
(pcDNA3–1, pcDNA3–2) were developed and analyzed for CA-AKT ex-
pression by Western blotting. Endogenous AKT and transfected consti-
tutively active AKT (CA-AKT) are indicated. B, AKT increases pS2 but
not c-Myc expression. Total RNA (20 mg) from cells grown in PR-free
MEM 1 CCS with or without treatment for 1 h was subjected to
Northern analysis with indicated probes. The integrity of RNA was
verified by reprobing the blot with 36B4 ribosomal protein gene cDNA.
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Also note that we reproducibly observed ;20% increase in the
basal growth rate of untreated CA-AKT compared with un-
treated pcDNA3 cells. Significantly, 4-HT was more efficient in
inhibiting the growth of pcDNA3 compared with CA-AKT cells,
indicating that AKT reduces 4-HT sensitivity of MCF-7 cells. In
contrast to 4-HT, CA-AKT cells were significantly growth-in-
FIG. 6. AKT overexpression confers tamoxifen resistance through inhibition of tamoxifen-induced apoptosis. A, growth rates of
untreated and estrogen-treated (1028 M) and/or 4-HT-treated (1026 M) pcDNA3–1 and CA-AKT-4 cells were measured by trypan blue exclusion and
manual counting at specific intervals. CA-AKT cells were significantly more resistant to 4-HT than pcDNA3 cells. *, p , 0.0004 for 4-HT-treated
pcDNA3 versus 4-HT-treated CA-AKT cells (day 5). B, growth rates of untreated and estrogen-treated (1028 M) or ICI-182,780-treated (1027 M)
pcDNA3–1 and CA-AKT-4 cells. **, p 5 0.0001 for untreated versus ICI-treated pcDNA3 cells. **, p 5 0.0078 for untreated versus ICI-treated
CA-AKT-4 cells. C, pcDNA3 and CA-AKT cells arrest at G0/G1 phase at a similar rate after 4-HT treatment. Cell cycle distribution was determined
by flow cytometric analysis of propidium iodide-stained cells. D, AKT inhibits 4-HT-induced apoptosis. Cells were treated with 4-HT (1026 M) for
72 h, and rate of apoptosis was measured by annexin V labeling. **, p , 0.0001 for percentage of apoptosis in 4-HT-treated CA-AKT versus
4-HT-treated pcDNA3 cells. ***, p 5 0.59 for untreated versus 4-HT-treated CA-AKT cells
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hibited by the pure anti-estrogen ICI-182,780 (Fig. 6B), which
inhibits ERa activity by preventing DNA binding and enhanc-
ing degradation (30). These results suggest that modulation of
ERa activity by AKT is responsible for 4-HT resistance of
CA-AKT cells, although we can not completely rule out the
involvement of ERa-independent anti-apoptotic activity of AKT
in 4-HT resistance.
Reduced sensitivity of CA-AKT cells to 4-HT could be due to
either loss of 4-HT-induced cell cycle arrest at G0/G1 or inhibi-
tion of 4-HT-induced apoptosis. To resolve this issue, we meas-
ured the cell cycle distribution of untreated and 4-HT-treated
pcDNA3 and CA-AKT cells. Both pcDNA3 and CA-AKT cells
accumulated at G0/G1 phase at a similar rate after 4-HT treat-
ment (Fig. 6C). Apoptosis of untreated and 4-HT-treated (1026
M for 72 h) pcDNA3 and CA-AKT cells were measured by
annexin V labeling and fluorescence microscopy (Fig. 6D). A
significantly higher percentage of pcDNA3 cells (31%) were
apoptotic when compared with CA-AKT cells (12%) after 4-HT
treatment. AKT therefore inhibits 4-HT-induced apoptosis but
not cell cycle arrest of MCF-7 cells.
AKT Increases Bcl-2 but Not Cyclin D1 Expression—Western
blot analysis of untreated and estrogen-treated cell extracts
was performed to identify estrogen-regulated cell cycle and
anti-apoptotic genes that are overexpressed in CA-AKT cells
(Fig. 7). Cyclin D1 expression proved estrogen-inducible in both
cell types. AKT had no significant effect on cyclin D1 expres-
sion. The known anti-apoptotic and estrogen-inducible Bcl-2
gene (31) was expressed at very low levels and did not appear
to be up-regulated by estrogen in pcDNA3 cells. In CA-AKT-2
cells, which expresses lower levels of AKT than CA-AKT-4
cells, estrogen dramatically increased Bcl-2 expression. In CA-
AKT-4 cells, Bcl-2 is constitutively overexpressed. Expression
of anti-apoptotic Bcl-XL and pro-apoptotic BAK and BAX was
similar in both pcDNA3 and CA-AKT cells. These results sug-
gest that AKT specifically increases Bcl-2 expression in MCF-7
cells. Because Bcl-2 overexpression in CA-AKT-2 cells was ob-
served only in the presence of estrogen, it is likely that in-
creased Bcl-2 expression in CA-AKT cells requires ERa
activity.
DISCUSSION
In this report, we demonstrate that PI 3-kinase/AKT signal-
ing pathway modulates ERa activity in vivo, which correlates
with phosphorylation of Ser-167 by AKT in vitro. Recent stud-
ies indicate that estrogen promotes association of ERa with
IGF-1 receptor and p85 subunit of PI 3-kinase in the plasma
membrane, which leads to AKT activation (10, 32). Our results
suggest that AKT serves as a functional link between mem-
brane-associated and nuclear ERa. By phosphorylating Ser-
167, AKT may modulate coactivator:AF-1 and/or corepressor:
AF-1 interactions in the nucleus. Consistent with this
possibility, previous studies have shown that phosphorylation
of Ser-118 of ERa alters both coactivator:AF-1 and corepressor:
AF-1 interactions (33, 34).
AF-1 region of ERa contains phosphorylation sites for a
number of kinases including MAPK and cyclin A/cdk2 (6, 28,
35). Some of these sites are conserved between ERa and ERb
(36). However, AKT phosphorylation site is present only in ERa
(36). ERs exist as homodimers as well as ERazERb het-
erodimers, and these combinations have different affinity for
EREs (37, 38). Therefore, induction of ERE containing genes
upon activation of AKT may be cell type-dependent. Further-
more, regulation of ERa activity by AKT may be controlled by
p90RSK1 as it can also phosphorylate Ser-167 (26). Finally,
MAPK may indirectly control AKT-mediated activation of ERa
as it can activate p90RSK1 (39).
We observed up-regulation of pS2, MIC-1, and Bcl-2 but not
c-Myc in CA-AKT-overexpressing cells (Fig. 5B). These results
suggest that the ability of AKT to induce ERE-containing genes
is promoter context-dependent. Because 4-HT repressed pS2
but not MIC-1 and Bcl-2 expression in CA-AKT cells, promoter
context may also play a role in determining the ability of 4-HT
to suppress AKT-mediated activation of estrogen-responsive
genes (Fig. 5B and data not shown). Both pS2 and Bcl-2 are
well characterized estrogen-regulated genes, whereas MIC-1
promoter is yet to be characterized. While induction of pS2 by
estrogen requires an ERE (40), activation of Bcl-2 by estrogen
requires a SP-1 binding site, cAMP response element-binding
protein binding site, and an ERE in the Bcl-2 promoter (31, 41).
Interestingly, cAMP response element-binding protein binding
site is required for AKT-mediated increase in Bcl-2 (42). There-
fore, it is likely that the ability of 4-HT to repress AKT-medi-
ated activation of ERE-containing promoters is determined by
promoter elements other than ERE. Alternatively, AKT may
activate certain ERE-containing promoters independent of
ERa, which is not subject to repression by 4-HT. Additional
experiments with dominant negative mutants of ERa (43, 44)
are essential to distinguish between these possibilities.
Our results indicate that activation of the PI 3-kinase/AKT
pathway leads to increased Bcl-2 expression, which correlates
with 4-HT resistance in breast cancer cells. Consistent with our
results, Her2/Neu-mediated 4-HT resistance in MCF-7 corre-
lates with Bcl-2 overexpression (45). However, the results of
FIG. 7. AKT up-regulates Bcl-2. Whole cell extracts from untreated
and estrogen-treated (1028 M) pcDNA3 and CA-AKT cells were sub-
jected to Western analysis using the indicated antibodies. AKT overex-
pression led to specific up-regulation of the anti-apoptotic Bcl-2 gene.
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our cell culture studies are inconsistent with clinical observa-
tions that correlate high Bcl-2 expression with favorable re-
sponse to tamoxifen therapy and prolonged disease-free inter-
vals (46). It is possible that Bcl-2 works in concert with
additional anti-apoptotic proteins to confer tamoxifen resist-
ance, which is in accordance with the proposal that overall level
of Bcl-2 family anti-apoptotic proteins dictates cellular re-
sponse to therapy (47).
The PI 3-kinase/AKT pathway is the major survival pathway
for a wide variety of cultured cell types (9). ERa may be the
central element in this survival pathway, at least in certain cell
types. Broader implications of our results are on endometrial
cancers as well as on Cowden’s disease patients, who show a
30–50% incidence of breast cancer in affected females (16). In
both neoplastic conditions, AKT activity is increased due to
mutation of PTEN. The PI 3-kinase/AKT pathway, therefore,
may be an ideal target for therapeutic intervention in these
cancers.
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